Introduction
============

Osteoarthritis (OA) is the most common joint disease with characteristics of progressive loss of joint cartilage, changes in the synovial membrane, and reduced viscosity of the synovial fluid.[@b1-dddt-12-445] More than 30% of people over 50 years of age suffer from knee OA based on radiographic imaging.[@b2-dddt-12-445] The need for knee arthroplasty has significantly increased, resulting in economic burdens from pain control and work performance loss with an increase in life expectancy[@b3-dddt-12-445] and the obesity epidemic.[@b4-dddt-12-445],[@b5-dddt-12-445]

Despite societal and health care advances, there are no medications or surgical interventions yet proven to alter the course of OA development. Topical medications are often used intra-articularly to relieve pain and increase joint functions, but they are not effective in cases of severe OA.[@b6-dddt-12-445] Intra-articular hyaluronic acid (HA) injection is widely used for treating knee OA, which provides treatment efficacy due to its visco-induction properties of increasing joint lubrication, as reported in many studies and meta-analysis.[@b7-dddt-12-445],[@b8-dddt-12-445]

The promotion of growth factors in cartilage repair has been studied in vitro and in vivo[@b9-dddt-12-445]--[@b12-dddt-12-445] to stimulate cell functions, such as proliferation and differentiation, matrix synthesis, and chondrocyte metabolism.[@b13-dddt-12-445] Platelet-rich plasma (PRP) is an autologous concentration of human platelets by centrifugation of the patient's blood,[@b14-dddt-12-445] which contains many components, including growth factors, cytokines, and many other mediators.[@b13-dddt-12-445],[@b15-dddt-12-445],[@b16-dddt-12-445] In a systematic review, Kon et al concluded that published studies support the application of PRP in the treatment of tendinous, ligamentous, cartilaginous, and muscular injuries.[@b17-dddt-12-445] Similarly, Laudy et al reported that PRP injections provide more pain relief than placebo injections in knee OA. However, they acknowledged that the level of evidence was "limited" due to the high risk of bias.[@b18-dddt-12-445]

Many studies compared PRP and HA to determine which was better and have not achieved consensus in terms of pain relief and function recovery. In a rabbit model of knee OA, Liu et al reported that PRP is better in promoting the restoration of the cartilage.[@b19-dddt-12-445] Sanchez et al showed superior short-term results in alleviating symptoms of mild to moderate OA of the knee for PRP compared to HA in a randomized controlled trial.[@b20-dddt-12-445] However, no difference was found between HA and PRP in the patient-reported Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score at 24 or 52 weeks in the study by Cole et al.[@b21-dddt-12-445] A meta-analysis published in 2016 showed that PRP was more effective than HA.[@b22-dddt-12-445] However, only seven studies were included in this meta-analysis, and one was a retrospective study.[@b23-dddt-12-445] More randomized trials were published later. Therefore, there is a need to update the comparison between PRP and HA. We aim to identify all prospective, randomized trials published to date to provide the latest insight on the efficacy of the use of PRP and HA in treating knee OA.

Materials and methods
=====================

The present study was completed according to the preferred reporting items for systematic review and meta-analyses (PRISMA) statement.

Search strategy
---------------

To identify all possible articles that meet the predefined inclusion criteria, an electronic search of PubMed (1966--September 2017), Embase (1980--September 2017), ScienceDirect (1985--September 2017), and Cochrane library (1966--September 2017) was performed according to the Cochrane Collaboration guidelines. Additionally, manual searches of the reference lists of all included studies were conducted to identify trials that the electronic search may have missed. All searches were conducted based on the following terms "osteoarthritis", "knee", "hyaluronic acid or HA", and "platelet-rich plasma or PRP" with the Boolean operators "AND or". Two reviewers independently assessed the titles and abstracts of reports identified by the electronic and manual searches. Full text articles were retrieved to facilitate identification based on the abstract, when necessary. Any disagreements were resolved through discussion.

Selection criteria
------------------

Trials with the following characteristics were included: 1) patients diagnosed with knee OA; 2) comparison of HA and PLP; 3) randomized or prospective trials; and 4) full text articles available with detailed information. We excluded retrospective articles, nonrandomized studies, and articles for which we were unable to obtain the full text and relevant data for pooled analysis.

Quality assessment
------------------

The quality assessment of randomized trials was conducted using the Cochrane Collaboration "Risk of bias". Prospective studies were assessed by the index for nonrandomized studies form. Disagreements were resolved by consensus or in consultation with the senior reviewer.

Data extraction
---------------

Two authors independently extracted all the information about the study design, publication year, patient demographics, PRP and HA interventions, parameters for evaluation, adverse events, and follow-up duration for each treatment group from the included articles. We attempted to contact authors for supplementary information when the reported data were inadequate.

Data analysis and statistical methods
-------------------------------------

Because different follow-up times were used in these identified articles, we pooled and calculated data from around a similar time frame. Data from follow-up in the second or third month were merged, as were data from week 48 or 52. The meta-analysis was performed using RevMan 5.1 for Windows (Cochrane Collaboration, Oxford, UK). Risk difference and 95% confidence intervals (CIs) were calculated for dichotomous outcomes, while the mean difference (MD) and 95% CI were calculated for continuous outcomes. Statistical heterogeneity was assessed using a standard chi-square test and was considered significant for *P*\<0.05 and *I*^2^ \>50%. When there was significant heterogeneity, pooled data were analyzed using a random effects model. Otherwise, a fixed effects model was used for the analysis.

Results
=======

Literature search
-----------------

[Figure 1](#f1-dddt-12-445){ref-type="fig"} shows the process of the study selection and inclusion. A total of 124 potential studies were identified with the first search strategy. Of these, 110 studies were excluded according to the eligibility criteria. No additional studies were obtained after the manual reference review. First, we identified 14 studies that satisfied the predefined inclusion criteria. Among these studies, Filardo et al published similar results comparing PRP and HA in 2012 and 2015. We excluded the article published in 2012 after careful comparison of the two studies. Eventually, three prospective studies[@b9-dddt-12-445],[@b24-dddt-12-445],[@b25-dddt-12-445] and ten randomized trials[@b20-dddt-12-445],[@b21-dddt-12-445],[@b26-dddt-12-445]--[@b33-dddt-12-445] were included in final quality assessment and data extraction.

Study characteristics
---------------------

Individual patient data were available from these articles except for data for those lost to follow-up. The characteristics of the included studies are summarized in [Table 1](#t1-dddt-12-445){ref-type="table"}. These studies were published from 2011 to 2017 with more female patients than male patients (895 versus 625). Comparable patients were included in the PRP group (788) and HA group (736). Grade 0 (Kellgren and Lawrence classification) was chondropathy of knee without clear OA appearance on X-ray. Early appearance was grades 1--3, while grade 4 was defined as advanced appearance. Three studies[@b9-dddt-12-445],[@b27-dddt-12-445],[@b30-dddt-12-445] enrolled 72 advanced knees, while only one study[@b9-dddt-12-445] included 62 grade 0 patients. Therefore, 1,390 participants (91.2%) in these studies were in the early stage from grades 1 to 3.

Quality assessment
------------------

For all randomized trials, there were no detailed descriptions on reporting bias and other biases. Performance and detection bias were not described in the studies by Cerza et al,[@b26-dddt-12-445] Raeissadat et al,[@b30-dddt-12-445] and Duymus et al.[@b32-dddt-12-445] Additionally, the patients in the study by Cerza et al were consecutively randomized into groups by admission to the hospital, causing selection bias. All methodological processes are shown in [Figure 2](#f2-dddt-12-445){ref-type="fig"}. For the other three prospective studies, the calculation of the sample size or unbiased assessment of the study endpoints could not be identified in the articles ([Table 2](#t2-dddt-12-445){ref-type="table"}).

Outcomes of the meta-analysis
-----------------------------

The WOMAC was the most used tool to evaluate the effects of PRP or HA in the included studies.[@b20-dddt-12-445],[@b21-dddt-12-445],[@b25-dddt-12-445]--[@b27-dddt-12-445],[@b30-dddt-12-445]--[@b32-dddt-12-445] However, different studies followed-up patients according to different protocols for baseline, 2 or 3, 6, and 12 months. Because of these data limitations, we can only evaluate the effects of the intervention at different times. Furthermore, we cocalculated the data from the second and third months after the intervention. Based on the available data pooled from six studies, there was no significant difference between these two groups when they were enrolled (MD=0.88; 95% CI: −3.45 to 5.21; *P*=0.69; *I*^2^=76%). The PRP performed better than the HA after 3 months of treatment (MD=−10.82; 95% CI: −19.74 to −1.91; *P*=0.02; *I*^2^=89%). Taking time into consideration, this advantage continued at 6 months (MD=−14.18; 95% CI: −26.12 to −2.23; *P*=0.02; *I*^2^=95%) and 12 months (MD=−15.25; 95% CI: −22.17 to −8.32; *P*\<0.01; *I*^2^=81%).

The WOMAC consists of three parts, including pain, stiffness, and physical function. For knee pain, the pooled data showed that patients treated with PRP had less pain than those treated with HA at 6 months (MD=−2.0; 95% CI: −3.60 to −0.39; *P*=0.01; *I*^2^=90%) and 12 months (MD=−2.22; 95% CI: −3.65 to −0.79; *P*=0.002; *I*^2^=92%). VAS was another parameter used to evaluate pain after treatment in four studies.[@b24-dddt-12-445],[@b31-dddt-12-445]--[@b33-dddt-12-445] Two studies showed no significant difference between PRP and HA, while the others showed better pain reduction for PRP. Available data from Say et al and Duymus et al showed that PRP and HA performed similarly at 3 months (MD=−0.98; 95% CI: −2.55 to 0.59; *P*=0.22; *I*^2^=90%) and 6 months (MD=−0.82; 95% CI: −1.80 to 0.16; *P*=0.1; *I*^2^=83%).

Physical function evaluated by the WOMAC was reported in four studies and showed that patients treated with PRP and HA had similar function recovery after 6 months of treatment (MD=−5.78; 95% CI: −14.73 to 3.16; *P*=0.21; *I*^2^=92%). However, PRP performed better than HA at 12 months (MD=−11.17; 95% CI: −16.37 to −5.98; *P*\<0.01; *I*^2^=83%). The EuroQol-visual analogue scales (EQ VAS) was also used to demonstrate functional recovery after treatment in four studies.[@b9-dddt-12-445],[@b21-dddt-12-445],[@b28-dddt-12-445],[@b29-dddt-12-445] The results showed that PRP and HA performed similarly at 6 months (MD=2.19; 95% CI: −11.47 to 15.85; *P*=0.75; *I*^2^=98%) and 12 months (MD=−4.64; 95% CI: −21.79 to 12.51; *P*=0.60; *I*^2^=98%). In the study by Kon et al,[@b9-dddt-12-445] high- and low-molecular weight H65As were compared to PRP, while one versus three injections of PRP were compared in a study by Gormeli et al.[@b29-dddt-12-445] The use of high-molecular weight HA (HWHA) versus low-molecular weight HA (LWHA) or three injections versus one injection did not significantly influence the result.

The Subjective International Knee Documentation Committee (IKDC) was reported in several studies.[@b9-dddt-12-445],[@b21-dddt-12-445],[@b28-dddt-12-445],[@b29-dddt-12-445] Patients in the PRP group showed better IKDC scores than those in the HA group (MD=8.53; 95% CI: 4.52 to 12.53; *P*\<0.01; *I*^2^=79%) at 6 months. The difference disappeared at 12 months (MD=6.84; 95% CI: −1.96 to 15.63; *P*=0.13; *I*^2^=91%). These details are summarized in [Table 3](#t3-dddt-12-445){ref-type="table"}.

Discussion
==========

OA in the knee, as a chronic progressive joint disease, is the second leading cause of loss of function;[@b34-dddt-12-445] followed by a heavy economic and social burden.[@b3-dddt-12-445] The etiology and pathogenesis of knee osteoarthritis are still not clear,[@b35-dddt-12-445] the main pathological change is the articular cartilage degeneration, with involved synovial fluid components changing as well.[@b36-dddt-12-445] Hyaluronic acid synthesis is demolished and diluted by effusion, which made the molecular weight and concentration of endogenous HA decrease in the knee articular cavity of OA patients.[@b37-dddt-12-445],[@b38-dddt-12-445] All of the changes reduced the viscoelasticity of articular cartilage, and lowered the capability to resist mechanical stresses and damage.

As the most important component of synovial fluid, HA is an unbranched polyanionic polymer composed of N-acetyl-D-glucosamine and D-glucosamine, which plays a role in nutrition and protection in the joints.[@b40-dddt-12-445] The latest treatment guidelines for OA in the knee do not recommend HA as the main treatment;[@b41-dddt-12-445] however, animal experiments have shown that HA plays a significant role in anti-inflammatory, anti-apoptotic, anti-angiogenic, and anti-fibrosis.[@b42-dddt-12-445] A large number of clinical studies also demonstrated that HA has the effect of relieving joint pain and improving joint function.[@b43-dddt-12-445]--[@b45-dddt-12-445] Some scholars demonstrated that HA treatment on severe knee osteoarthritis is not effective. The effectiveness of HA decreases after the multiple applications.[@b46-dddt-12-445],[@b47-dddt-12-445] Furthermore, HA doesn't improve regeneration of damage cartilage particularly in the elder patients.[@b48-dddt-12-445],[@b49-dddt-12-445]

PRP acts as a vector for large growth factors,[@b12-dddt-12-445] which have the function of promoting tissue repair,[@b50-dddt-12-445] which is increasingly being used in the treatment of OA. PRP maintains 4.6 times the platelet concentration compared to the original value. Some reports believe that PRP may induce precursor cells' migration, proliferation, and differentiation in the synovial fat pad or cartilage. Thereby, PRP could promote the repair of damaged cartilage,[@b51-dddt-12-445],[@b52-dddt-12-445] while reducing pain and the inflammatory response effect.[@b53-dddt-12-445]

For this study, the data based on three prospective and ten randomized trials showed no definitively better results for PRP than HA. Different results can be seen in the WOMAC, EQ VAS, VAS, IKDC, and other evaluation tools. Three prospective trials were included. Quality assessment scores ranged from 16 to 20. No prospective calculation of the sample size was described in nonrandomized controlled trials. In addition, the assessment of the study endpoints was biased. All these shortcomings weaken the level of evidence.

There were insufficient data to conduct a subgroup analysis. Based on careful review of the included studies, we made a couple of observations. First, the components of PRP and HA were different among these studies. Although the PRP was produced from the patients' blood by a similar method of centrifugation, the platelet concentrations differed. Additionally, other products, such as cellular products and mediators, varied between the studies. HA was provided by several manufacturers with various molecular weights. Based on the description by Kon et al[@b9-dddt-12-445] we defined LWHA as a molecular weight less than 1,000 kDa and HWHA as more than 1,000 kDa. HWHA was used in studies by Kon et al,[@b9-dddt-12-445] Vaquerizo et al,[@b27-dddt-12-445] Filardo et al,[@b28-dddt-12-445] Lana et al,[@b31-dddt-12-445] and Duymus et al,[@b32-dddt-12-445] while LWHA was used in studies by Kon et al,[@b9-dddt-12-445] Say et al,[@b24-dddt-12-445] Raeissadat et al,[@b30-dddt-12-445] Montanez-Heredia et al,[@b33-dddt-12-445] and Cole et al.[@b21-dddt-12-445] The other studies did not provide detailed information about the HA molecular weight.[@b20-dddt-12-445],[@b25-dddt-12-445],[@b26-dddt-12-445],[@b29-dddt-12-445]

The number of injections also varied among these studies, including a single injection,[@b24-dddt-12-445],[@b31-dddt-12-445] two injections[@b30-dddt-12-445],[@b32-dddt-12-445] or multiple injections.[@b26-dddt-12-445] For the studies with multiple injections, the interval between the two injections was also different. The interval of 1 month was adopted in the study by Raeissadat et al[@b30-dddt-12-445] and 2 weeks was used by Kon et al,[@b9-dddt-12-445] Vaquerizo et al,[@b27-dddt-12-445] Duymus et al,[@b32-dddt-12-445] and Montanez-Heredia et al.[@b33-dddt-12-445] In a prospective, randomized trial, Gormeli et al compared HA with multiple- or single-dose PRP.[@b29-dddt-12-445] There were no differences between HA and single-dose PRP, while multiple-dose PRP was better than both treatments.

The pathology of knee OA changes from chondropathy without appearance on X-ray. Patients at different stages do not have the same response to the same treatment. Filardo et al concluded that PRP was more effective in young patients with early or moderate stages of arthrosis, but it had a limited effect in cases of advanced OA.[@b54-dddt-12-445] Chang et al evaluated the effects of intra-articular injection of PRP or HA in a systematic review and reported better results among those patients with milder forms of OA than advanced forms.[@b55-dddt-12-445] Most patients in our analysis suffered from early stage knee OA, ranging from grades 1 to 3, for a total of 1,390 participants (91.2%). There were 72 grade 4 knee OA patients enrolled in three studies,[@b9-dddt-12-445],[@b27-dddt-12-445],[@b30-dddt-12-445] which may have altered the treatment effect.

Additionally, previous studies showed that the efficacy of intra-articular injection of HA or PRP depended on time. Filardo et al reported improvement after 2 months of treatment, which was confirmed at 6 months of follow-up, and there was a tendency to worsen after 6 to 12 months.[@b56-dddt-12-445] Similar results were reported in another study in which the positive therapeutic efficacy of HA peaked at 8 weeks and lasted for up to 6 months.[@b47-dddt-12-445] This tendency may influence the calculation and analysis in our studies because different test points were used, and we combined data from 2 and 3 months.

Beyond those differences in the study intervention, the mechanism of PRP and HA in the change in knee OA was another important factor that influenced the treatment effects. The beneficial effects of HA may be attributable to improved lubrication based on the viscoelasticity and/or the improvement of the intra-articular environment by rebuilding the barrier between the synovial membrane and the articular surface.[@b57-dddt-12-445] The growth factors secreted from active platelets have a fundamental function to stimulate proliferation and differentiation of chondrocytes, regulate collagenase secretion, and regenerate cartilage.[@b58-dddt-12-445] HA acts as a lubricator, while PRP provides many factors to stimulate the synovial membrane and surrounding tissues. The combination of HA and PRP may be more effective than either alone, as Lana et al concluded (the combination of HA and PRP resulted in better outcomes than HA alone at up to 1 year and PRP alone at up to 3 months).[@b31-dddt-12-445]

Our current study included the most recent trials comparing HA and PRP, though we must acknowledge the limitations of the analysis. The first and serious limitation was that there was significant heterogeneity in each calculation. Second, too many evaluation tools were used across the different studies such that the highest number of studies that used any single evaluation tool was five studies for the WOMAC score at 6 months. A funnel plot could not be drawn to analyze the publication bias. These limitations weakened our ability to draw a definitive study conclusion.

Conclusion
==========

PRP injections reduced pain more effectively than HA injections in OA of the knee at 6 and 12 months of follow-up evaluated by WOMAC pain score, while the VAS showed no significant difference at 3 and 6 months. Additionally, similar results were observed for the function recovery according to the WOMAC function score and EQ VAS. Due to the limited quality and data of the evidence currently available, more high-quality randomized controlled trials are required.
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###### 

Detailed information of the included studies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                        Group                                              Age\         Gender\   OA type\         BMI (kg/m^2^)   Intervention                                    Follow-up\
                                                                                                      (years)      (M/F)     (C/E/A)                                                                          (months)
  ------------------------------------------------ -------------------------------------------------- ------------ --------- ---------------- --------------- ----------------------------------------------- -------------
  Kon et al, 2011[@b9-dddt-12-445]                 PRP\                                               50.6±13.8\   30/20\    C22; E20; A8\    24.6±3.2\       3 times, 5 mL, every 2 weeks\                   2, 6
                                                   HWHA\                                              54.9±12.6\   25/25\    C21; E19; A10\   24.8±3.5\       30 mg/2 mL, 1,000 to 2,900 kDa\                 
                                                   LWHA                                               53.2±13.0    27/23     C19; E22; A9     26.2±2.2        20 mg/2 mL, 500 to 730 kDa                      

  Cerza et al,[@b26-dddt-12-445] 2012              PRP\                                               66.5±11.3\   25/35\    E 21/24/15\      N\              4 times, 5.5 mL, weekly\                        1, 2, 6
                                                   HA                                                 66.2±10.6    28/32     E 25/22/13       N               4 times, 20 mg/2 mL                             

  Sanchez et al,[@b20-dddt-12-445] 2012            PRP\                                               60.5±7.9\    43/46\    E 45/32/12\      27.9±2.9\       3 times, 8 mL, weekly\                          1, 2, 6
                                                   HA                                                 58.9±8.2     42/45     E 42/32/11       28.2±2.7        3 times                                         

  Spakova et al,[@b25-dddt-12-445] 2012            PRP\                                               52.8±12.4\   33/27\    E 2/39/19\       27.9±4.1\       3 times, 3 mL, weekly\                          3, 6
                                                   HA                                                 53.2±14.5    31/29     E 2/37/21        28.3±4.0        3 times                                         

  Say et al,[@b24-dddt-12-445] 2013                PRP\                                               55.2±7.8\    5/40\     E 1/17/27\       32.4±4.0\       1 time\                                         3, 6
                                                   LWHA                                               56.2±5.1     6/39      E 1/15/29        32.3±3.3        3 times, 25 mg/2.5 mL, 730 to 900 kDa, weekly   

  Vaquerizo et al,[@b27-dddt-12-445] 2013          PRP\                                               62.4±6.6\    16/32\    E 0/14/26; A8\   30.7±3.6\       3 times, 8 mL, every 2 weeks\                   6, 12
                                                   HWHA                                               64.8±7.7     22/26     E 0/18/21; A9    31.0±4.6        1 time, 60 mg/3 mL                              

  Filardo et al,[@b28-dddt-12-445] 2015            PRP\                                               53.3±13.2\   60/34\    E 2.0±1.1\       26.6±4.0\       3 times, 5 mL, weekly\                          2, 6, 12
                                                   HWHA                                               57.6±11.8    52/37     E 2.0±1.1        26.9±4.4        3 times, 20 mg/2 mL, \>1,500 kDa, weekly        

  Gormeli et al,[@b29-dddt-12-445] 2017            PRP[\*](#tfn1-dddt-12-445){ref-type="table-fn"}\   53.7±13.1\   23/16\    E 26; A13\       28.7±4.8\       3 times, 5 mL, weekly\                          6
                                                   PRP[\#](#tfn2-dddt-12-445){ref-type="table-fn"}\   53.8±13.4\   25/19\    E 25; A14\       28.4±4.4\       1 time, 5 mL\                                   
                                                   HA                                                 53.5±14      22/17     E 27; A13        29.7±3.7        3 times, 20 mg/2 mL, weekly                     

  Raeissadat et al,[@b30-dddt-12-445] 2015         PRP\                                               56.9±9.1\    8/69\     E6/44/38; A12\   28.2±4.6\       2 times, 5 mL, monthly\                         1, 6, 12
                                                   LWHA                                               61.1±7.5     15/47     E0/47/37; A16    27.0±4.2        3 times, 20 mg/2 mL, 500 to 730 kDa, monthly    

  Lana et al,[@b31-dddt-12-445] 2016               PRP\                                               60.9±7\      7/29\     E 9/14/13\       27.4±6.9\       1 time, 5 mL\                                   1, 3, 6, 12
                                                   HWHA\                                              60±6.6\      3/33\     E 9/16/11\       28.2±8.8\       20 mg/2 mL, 2,400 to 3,600 kDa\                 
                                                   P&A                                                62±6.1       6/27      E 5/14/14        29.2±7.3        5 mL+2 mL                                       

  Duymus et al,[@b32-dddt-12-445] 2017             PRP\                                               60.4±5.1\    1/32\     E 0/22/11\       27.6±4.6\       2 times, 5 mL per time, every 2 weeks\          1, 3, 6, 12
                                                   HWHA                                               60.3±9.1     1/33      E 0/24/10        28.4±3.6        40 mg/2 mL, 1,600 kDa                           

  Montanez-Heredia et al,[@b33-dddt-12-445] 2016   PRP\                                               66.3±8.3\    12/15\    E 5/10/12\       29.0±5.5\       3 times, every 2 weeks\                         3, 6
                                                   LWHA                                               61.5±8.6     9/17      E 2/9/15         30.4±4.9        3 times, 25 mg/2.5 mL, 799 kDa                  

  Cole et al,[@b21-dddt-12-445] 2017               PRP\                                               55.9±10.4\   28/21\    E 3/2620\        27.4±3.9\       3 times, 4 mL, weekly\                          3, 6, 12
                                                   LWHA                                               56.8±10.5    20/30     E 1/27/22        29.0±6.4        3 times, 16 mg/2 mL, 6,000 kDa                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Three injections of PRP;

one injection of PRP. OA type (C/E/A): chondropathy, Kellgren grade 0/early, Kellgren grade I to III/advanced, Kellgren grade IV.

**Abbreviations:** OA, osteoarthritis; BMI, body mass index; PRP, platelet-rich plasma; HA, hyaluronic acid; HWHA, high-molecular weight hyaluronic acid; LWHA, low-molecular weight hyaluronic acid; P&A, PRP and HA.

###### 

Quality assessment for nonrandomized trials

  Quality assessment for nonrandomized trials           Kon et al[@b9-dddt-12-445]   Say et al[@b24-dddt-12-445]   Spakova et al[@b25-dddt-12-445]
  ----------------------------------------------------- ---------------------------- ----------------------------- ---------------------------------
  A clearly stated aim                                  2                            2                             2
  Inclusion of consecutive patients                     2                            0                             0
  Prospective data collection                           0                            0                             0
  Endpoints appropriate to the aim of the study         2                            2                             2
  Unbiased assessment of the study endpoint             0                            0                             0
  A follow-up period appropriate to the aims of study   2                            2                             2
  Less than 5% loss to follow-up                        2                            2                             2
  Prospective calculation of the sample size            2                            0                             2
  An adequate control group                             2                            2                             2
  Contemporary groups                                   2                            2                             2
  Baseline equivalence of groups                        2                            2                             2
  Adequate statistical analyses                         2                            2                             2
  Total score                                           20                           16                            18

###### 

Results of the meta-analysis

  Follow-up        Evaluation tools    Studies   Patients (PRP/HA)   MD                95% CI            *P*\<0.05   *I*^2^
  ---------------- ------------------- --------- ------------------- ----------------- ----------------- ----------- --------
  3 months         WOMAC total score   3         153/154             −10.82            −19.74 to −1.91   Yes         89%
  WOMAC pain       2                   82/84     −0.5                −1.66 to 0.66     No                81%         
  VAS              2                   78/79     −0.98               −2.55 to 0.59     No                95%         
  EQ VAS           2                   144/139   5.91                −1.51 to 13.34    No                79%         
  6 months         WOMAC total score   5         290/289             −14.18            −26.12 to −2.23   Yes         95%
  WOMAC pain       4                   219/219   −2.0                −3.60 to −0.39    Yes               90%         
  VAS              2                   78/79     −0.82               −1.80 to 0.16     No                83%         
  WOMAC function   3                   170/169   −5.78               −14.73 to 3.16    No                92%         
  EQ VAS           4                   232/228   2.19                −11.47 to 15.85   No                98%         
  IKDC             4                   232/228   8.53                4.52 to 12.53     Yes               79%         
  12 months        WOMAC total score   4         207/194             −15.25            −22.17 to −8.32   Yes         81%
  WOMAC pain       3                   158/144   −2.22               −3.65 to −0.79    Yes               92%         
  WOMAC function   3                   158/144   −11.17              −16.37 to −5.98   Yes               83%         
  EQ VAS           2                   143/139   −4.64               −21.79 to 12.51   No                98%         
  IKDC             2                   143/139   6.84                −1.96 to 15.63    No                91%         

**Abbreviations:** CI, confidence interval; EQ VAS, EuroQol-visual analog scales; HA, hyaluronic acid; IKDC, Subjective International Knee Documentation Committee; MD, mean difference; PRP, platelet-rich plasma; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
